Revisiting the Theory That Some Chronic Conditions Stem from Endocannabinoid Deficiency | Research

The takeaway

A decade after the clinical endocannabinoid deficiency hypothesis was first proposed, the authors argue growing evidence supports the idea that low endocannabinoid tone underlies migraine, fibromyalgia, and irritable bowel syndrome.

Read this if you have migraine, fibromyalgia, or IBS and want to understand the endocannabinoid deficiency theory.

Endocannabinoid deficiency proposed as a shared mechanism for migraine, fibromyalgia, and IBS

What the researchers found

The review revisits Ethan Russo's 2004 hypothesis that migraine, fibromyalgia, irritable bowel syndrome, and related conditions may share a common underlying cause: deficient endocannabinoid system function. Ten years later, the authors report that subsequent research has supported this concept.

Evidence accumulated since the original proposal showed that cannabinoids can block spinal, peripheral, and gastrointestinal pain mechanisms relevant to these conditions. The list of conditions potentially linked to endocannabinoid deficiency has expanded beyond the original three.

The authors conclude that clinical experience is bearing out the theoretical framework, and call for more clinical trials to demonstrate the usefulness of medical cannabis for these conditions.

Why it matters

If endocannabinoid deficiency is a real clinical entity underlying multiple treatment-resistant conditions, it would provide a unifying explanation for why cannabis helps some patients with migraine, fibromyalgia, and IBS when other treatments have failed.

The numbers in context

Review covers the decade from 2004-2014. Conditions discussed: migraine, fibromyalgia, irritable bowel syndrome, and a "growing list" of other medical conditions.

How the study worked

This is a narrative review updating the clinical endocannabinoid deficiency concept proposed in 2004. The authors searched the National Library of Medicine database and other sources for literature published in the decade since the original hypothesis.

What this study cannot tell us

This is a brief narrative review with apparent advocacy tone. The evidence cited is largely indirect, and no clinical trials specifically tested the endocannabinoid deficiency hypothesis. The review does not critically evaluate contradictory evidence. Measuring clinical endocannabinoid levels remains technically challenging.

How to read the evidence

This is a brief narrative review of an unproven hypothesis. The supporting evidence is largely indirect and preclinical.

When this study was published

Published in 2014. The CECD hypothesis continues to be discussed and debated, with some additional supporting evidence but no definitive clinical validation.

The bigger picture

The endocannabinoid deficiency hypothesis has been influential in shaping medical cannabis research and advocacy. While intriguing, the concept remains controversial in mainstream medicine due to the difficulty of measuring endocannabinoid levels clinically and the lack of large-scale clinical trials validating the treatment approach.

Questions still open

Can endocannabinoid levels be reliably measured in clinical settings? Would targeted endocannabinoid enhancement outperform whole-plant cannabis? Are the connections between these diverse conditions and endocannabinoid deficiency causal or coincidental?

Common questions

What is clinical endocannabinoid deficiency?

It is a proposed condition where the body produces insufficient endocannabinoids, leading to heightened pain sensitivity, digestive problems, and other symptoms. The theory suggests this deficiency underlies certain chronic conditions that are difficult to treat with standard medications.

Is this hypothesis proven?

No. While some research supports the concept, it remains a hypothesis. Measuring endocannabinoid levels in clinical settings is difficult, and no large-scale clinical trials have specifically tested whether correcting an endocannabinoid deficiency improves these conditions.

Read the original research

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

Neuro endocrinology letters, 35(3), 198-201

View on PubMed ↗

Citation

Smith, Steele Clarke; Wagner, Mark S. (2014). Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?. Neuro endocrinology letters, 35(3), 198-201.